Literature DB >> 11161841

Thyroid carcinoma is characterized by genomic instability: evidence from p53 mutations.

B Shahedian1, Y Shi, M Zou, N R Farid.   

Abstract

p53 is a transcription factor with multifaceted regulatory functions in cell cycle progression, DNA repair, and programmed cell death. Inactivating mutations have been described in 50% of human cancers. These mutations appear to be important in tumor progression and response to chemotherapy and radiation treatment and thus clinical outcome. p53 mutations are found in 14% of malignant thyroid tumors and are more frequent in poorly differentiated and anaplastic tumors. Given that p53 is a late event in the notional multistep pathogenesis of cancer, we examined its mutation rates as a measure of genomic instability (hypermutability) of malignant thyroid tumors and also wondered whether radiation enhances that proclivity to genomic instability. To that end we have extracted all available data from the p53 mutation database (http://www.perso@curie.fr), verified, extended, where applicable, and supplemented that information from published reports. We were able to identify 100 entries. The distribution of the p53 mutational events--deletions/insertions, transitions versus transversion mutations--was similar to that of the database as a whole. The silent mutation rate of 17.8%, not different from the expected 25%, is consistent with a random occurrence of these mutations. The silent mutation rate is 120 times that expected and is 6 times that of the database. Moreover, the distribution of p53 mutations is compatible with Poisson's distribution, which taken with silent mutation rates indicates that p53 is particularly hypermutable in thyroid carcinomas. Epigenetic deamination of CpG dinucleotide at highly oncogenic DNA-contact residues is a feature of poorly differentiated tumors and thus associated with tumor progression. The rates of p53 mutations (15.4%) in radiation-related cancers were very similar to those in apparently spontaneously arising tumors, although there was a highly significant heterogeneity (P < 0.0005) in the residues mutated. None involved CpG deamination. It is apparent that thyroid cancer exhibits remarkable genomic instability evidenced by p53 hypermutability. Spontaneous epigenetic mutational events are involved in tumor progression and while radiation increases the absolute prevalence of thyroid cancer in the susceptible it does not increase the rate of p53 mutation and seemingly targets different non-DNA-contact residues than those in spontaneously arising tumors. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11161841     DOI: 10.1006/mgme.2000.3114

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  11 in total

Review 1.  How to define follicular thyroid carcinoma?

Authors:  Kurt Werner Schmid; Nadir Rashad Farid
Journal:  Virchows Arch       Date:  2006-02-28       Impact factor: 4.064

2.  Metastatic Anaplastic Thyroid Carcinoma in Complete Remission: Morphological, Molecular, and Clinical Work-Up of a Rare Case.

Authors:  Adam Stenman; L Samuel Hellgren; Kenbugul Jatta; Martin Hysek; Maja Zemmler; Renske Altena; Inga-Lena Nilsson; Robert Bränström; Jan Zedenius; C Christofer Juhlin
Journal:  Endocr Pathol       Date:  2020-03       Impact factor: 3.943

Review 3.  Attenuating the p53 Pathway in Human Cancers: Many Means to the Same End.

Authors:  Amanda R Wasylishen; Guillermina Lozano
Journal:  Cold Spring Harb Perspect Med       Date:  2016-08-01       Impact factor: 6.915

Review 4.  P53 mutations in thyroid carcinoma: tidings from an old foe.

Authors:  N R Farid
Journal:  J Endocrinol Invest       Date:  2001 Jul-Aug       Impact factor: 4.256

5.  Significance of MDM2 and P14 ARF polymorphisms in susceptibility to differentiated thyroid carcinoma.

Authors:  Fenghua Zhang; Li Xu; Qingyi Wei; Xicheng Song; Erich M Sturgis; Guojun Li
Journal:  Surgery       Date:  2012-12-04       Impact factor: 3.982

6.  Mutations of TSHR and TP53 Genes in an Aggressive Clear Cell Follicular Carcinoma of the Thyroid.

Authors:  Guo-Xia Tong; Kokila Mody; Zhuo Wang; Diane Hamele-Bena; Marina N Nikiforova; Yuri E Nikiforov
Journal:  Endocr Pathol       Date:  2015-12       Impact factor: 3.943

7.  Transforming acidic coiled-coil 3 and Aurora-A interact in human thyrocytes and their expression is deregulated in thyroid cancer tissues.

Authors:  Salvatore Ulisse; Enke Baldini; Matteo Toller; Jean-Guy Delcros; Aurélie Guého; Francesco Curcio; Enrico De Antoni; Laura Giacomelli; Francesco S Ambesi-Impiombato; Sarah Bocchini; Massimino D'Armiento; Yannick Arlot-Bonnemains
Journal:  Endocr Relat Cancer       Date:  2007-09       Impact factor: 5.678

8.  p53 mutations associated with aging-related rise in cancer incidence rates.

Authors:  Richard B Richardson
Journal:  Cell Cycle       Date:  2013-07-01       Impact factor: 4.534

9.  Deregulated expression of Aurora kinases is not a prognostic biomarker in papillary thyroid cancer patients.

Authors:  Enke Baldini; Chiara Tuccilli; Natalie Prinzi; Salvatore Sorrenti; Laura Falvo; Corrado De Vito; Antonio Catania; Francesco Tartaglia; Renzo Mocini; Carmela Coccaro; Stefania Alessandrini; Susi Barollo; Caterina Mian; Alessandro Antonelli; Enrico De Antoni; Massimino D'Armiento; Salvatore Ulisse
Journal:  PLoS One       Date:  2015-03-25       Impact factor: 3.240

Review 10.  A new aurora in anaplastic thyroid cancer therapy.

Authors:  Enke Baldini; Massimino D'Armiento; Salvatore Ulisse
Journal:  Int J Endocrinol       Date:  2014-07-01       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.